Eastern Asia Pharmaceutical: Revenue in 2025 is 940 million yuan, a year-on-year decrease of 21.54%.

East Asia Pharmaceutical announced that in 2025, the company achieved operating income of 940 million yuan, a year-on-year decrease of 21.54%; with a net loss of 82 million yuan. By the end of 2025, the company's total assets were 3.38 billion yuan, a decrease of 6.15% from the beginning of the period, and the equity attributable to the owners of the parent company was 1.806 billion yuan, a decrease of 3.66% from the beginning of the period. In addition, the 690 million yuan "East Asia Convertible Bonds" issued on July 6, 2023, had fully utilized the funds raised as of December 31, 2025, and all special accounts had been cancelled.